A Houston-area company has created an easy-to-use health-check app for employees returning to work. Pexels

A Woodlands-based health services company recently announced a new app that can serve as a self-service pre-screening tool for COVID-19 to be used by employees to return to their workplace.

Axiom Medical created the CheckIn2Work app to make the transition into the workplace after the coronavirus crisis safer and easier, making it simple for businesses and offices to reopen after stay-at-home orders shut down workplaces during the height of the pandemic.

"Given the current challenges we have all experienced with COVID-19, we recognize the workplace will be forever changed," says Axiom Medical President and CEO Mark Robinson. "Our CheckIn2Work app simply adds another layer to protecting the health of team members, customers, and vendors from the risk of infectious disease in the workplace."

The app includes features such as a 24/7 self-service illness screening with the latest screening criteria approved by Chief Medical Officer Scott Cherry. The app also includes immediate access to U.S.-based Clearance Center for exposure/illness alerts, real-time reporting, and ongoing best practices to reduce the spread of the virus in the work environment.

When an app user is flagged as exposed to the virus, Axiom Medical's Rapid Response Contagious Respiratory Illness Assessment Clearance Center professionals can conduct secondary screening procedures via a phone call to confirm cases and eliminate false positives.

The app has 50,000 users already from Axiom's new and existing clients who have signed on to the platform. Some of their partners include BJ Services, Tyson Foods, ISS Facility Services, and Fort Bend Kia, Robinson says it creates safe and healthy facilities for both employees and customers.

"It enables our clients to be appropriately responsive to trying to screen out the infection in their workplace," says Robinson, "It also gives employees confidence that returning to work and exposing themselves to their coworkers is safe while providing customers who have contact with the employees with the confidence who they will be interacting with has been screened and cleared."

For the health services company, keeping employees safe has been the heart of their mission since it was founded more than two decades ago. Axiom Medical markets itself as an employer's outsourced "in house" medical department, managing a complete array of occupational health services such as scheduling exams, verifying results for accuracy, and maintaining records.

"Our focus is on the health of the worker in the workplace," says Robinson. "Both our traditional services and our new service all focus on keeping people as healthy as possible, returning them to work as quickly as possible after an injury or illness keeps them out of the workplace, and making sure they are tested for a variety of risks."

CheckIn2Work is now available on iOS and Android mobile devices including a web portal where employees can check in before work every day to check for symptoms of COVID-19. The app is adaptable with language settings in English and Spanish and allows for customizable questions to fit an organization's needs.

"I hope we can continue to take this seriously and take good precautions," says Robinson. "This is a really horrible disease, it isn't just about the people who die as a result, it's also about those who are permanently disabled because of it. Those weeks in a hospital are mirrored by more weeks in recovery before they can even think about working again."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston medtech firm secures $30M for neurosurgical robot

stroke surgery

Robotic neurosurgery is an exciting new frontier in medicine, and Houston-based medtech firm XCath is leading the charge with its revolutionary Iris robotic system. The company announced in March that it had secured $30 million in Series C funding to continue developing systems to tackle blood clots in the human brain.

“We are grateful to our investors for their conviction in our shared mission to improve clinical outcomes for patients impacted by endovascular diseases,” Eduardo Fonseca, CEO of XCath, said in a news release. “In 2025, the XCath team advanced the frontiers of endovascular robotics. This funding accelerates our commitment to expanding access to life-saving care so that where a patient lives no longer determines whether they live.”

XCath–which also has campuses in Pangyo, South Korea–has already achieved a number of remarkable firsts in robotic neurosurgery. The Iris is the only endovascular robotic system currently in development to perform intracranial navigation or neurointerventional treatment, and is the only robot in the world to have performed an intracranial neurovascular procedure involving the robotic manipulation of three devices.

These new Series C funds, which bring the company's total investment to $92 million, will go toward developing a clinical telerobot capable of performing a mechanical thrombectomy. This would bring unprecedented accuracy and precision to the surgical removal of brain clots, significantly reducing the risk of neurosurgery.

“Robotic surgery succeeds when innovation is paired with practical execution,” Dr. Fred Moll, chairman of the XCath board of directors, said in the release. “XCath has built a promising technology foundation, and just as importantly, a team that values rigor and appreciates perspective. I’m excited to support them as they take on the mission of globalizing access to gold-standard care for stroke patients.”

In November 2025, the Iris debuted under the control of Dr. Vitor Mendes Pereira at The Panama Clinic in Panama City, alongside local Principal Investigator Dr. Anastasio Ameijeiras Sibauste. It was only the second time in human history that a robot had been used for intracranial neurovascular intervention, and it established Iris as a viable technology in the fight against stroke.

“Treatment of stroke and other neurovascular diseases represents one of the most significant financial opportunities in healthcare, supported by positive reimbursement dynamics and strong demand from health systems,” Nicholas Drysdale, CFO of XCath, added in the release. “With our continued investor support and disciplined capital deployment, XCath is positioned to build a category-leading platform in endovascular robotics”.

Houston geothermal unicorn Fervo officially files for IPO

going public

Fervo Energy has officially filed for IPO.

The Houston-based geothermal unicorn filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission on April 17 to list its Class A common stock on the Nasdaq exchange. Fervo intends to be listed under the ticker symbol "FRVO."

The number and price of the shares have not yet been determined, according to a news release from Fervo. J.P. Morgan, BofA Securities, RBC Capital Markets and Barclays are leading the offering.

The highly anticipated filing comes as Fervo readies its flagship Cape Station geothermal project to deliver its first power later this year

"Today, miles-long lines for gasoline have been replaced by lines for electricity. Tech companies compete for megawatts to claim AI market share. Manufacturers jockey for power to strengthen American industry. Utilities demand clean, firm electricity to stabilize the grid," Fervo CEO Tim Latimer shared in the filing. "Fervo is prepared to serve all of these customers. Not with complex, idiosyncratic projects but with a simplified, standardized product capable of delivering around-the-clock, carbon-free power using proven oil and gas technology."

Fervo has been preparing to file for IPO for months. Axios Pro first reported that the company "quietly" filed for an IPO in January and estimated it would be valued between $2 billion and $3 billion.

Fervo also closed $421 million in non-recourse debt financing for the first phase of Cape Station last month and raised a $462 million Series E in December. The company also announced the addition of four heavyweights to its board of directors last week, including Meg Whitman, former CEO of eBay, Hewlett-Packard, and Spring-based HPE.

Fervo reported a net loss of $70.5 million for the 2025 fiscal year in the S-1 filing and a loss of $41.1 million in 2024.

Tracxn.com estimates that Fervo has raised $1.12 billion over 12 funding rounds. The company was founded in 2017 by Latimer and CTO Jack Norbeck.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

New UT Austin med center, anchored by MD Anderson, gets $1 billion gift

Future of Health

A donation announced Tuesday, April 21, breaks a major record at the University of Texas at Austin. Michael and Susan Dell are now UT Austin's first supporters to give $1 billion. In response, the university will create the UT Dell Campus for Advanced Research and the UT Dell Medical Center to "advance human health," per a press release.

The release also records "significant support" for undergraduate scholarships, student housing, and the Texas Advanced Computing Center for supercomputing research.

Both the new research campus and the UT Dell Medical Center will integrate advanced computing into their research and practices. At the medical center, the university hopes that will lead to "earlier detection, more precise and personalized care, and better health outcomes." The University of Texas MD Anderson Cancer Center will also be integrated into the new medical center.

That comes with a numeric goal measured in 10s: raise $10 billion and rank among the top 10 medical centers in the U.S., both in the next decade.

In the shorter term, the university will break ground on the medical center with architecture firm Skidmore, Owings & Merrill (SOM) "later this year."

“UT Austin, where Dell Technologies was founded from a dorm room, has always been a place where bold ideas become real-world impact,” said Michael and Susan Dell in a joint statement.

They continued, “What makes this moment so meaningful is the opportunity to build something that brings every part of the journey together — from how students learn, to how discoveries are made, to how care reaches families. By bringing together medicine, science and computing in one campus designed for the AI era, UT can create more opportunity, deliver better outcomes, and build a stronger future for communities across Texas and beyond.”

This is the second major gift this year for the planned multibillion-dollar medical center. In January, Tench Coxe, a former venture capitalist who’s a major shareholder in chipmaking giant Nvidia, and Simone Coxe, co-founder and former CEO of the Blanc & Otus PR firm, contributed $100 million$100 million.